Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
about
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.Preliminary results from a crowdsourcing experiment in immunohistochemistryNew Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index.Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.A novel model for Ki67 assessment in breast cancer.Quantitative histopathological assessment of ocular surface squamous neoplasia using digital image analysis.Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.21(st) century workflow: A proposalCholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesisA prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyComparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 scoreComparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays.Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurementInterobserver Variability of Ki-67 Measurement in Breast Cancer.The Bonar score revisited: region of evaluation significantly influences the standardized assessment of tendon degeneration.High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association ConsortiumPrognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.An international Ki67 reproducibility study.Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.Correlation between Ki67 and breast cancer prognosis.Automated objective determination of percentage of malignant nuclei for mutation testing.Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.Immunohistological diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD138-positive plasma cells.
P2860
Q27852034-9E7DEF1D-434F-4656-A253-9B6416F232E4Q28651551-0BFA1260-4462-4B70-AC73-A115567B5595Q30489246-9761536D-FA52-45B3-A9DA-A9108B965786Q31153510-9C62A5A8-728C-4EE5-B1F3-AAF70F9D0EA0Q33702468-67C7D89D-4856-4F9C-AE68-6BE1A07E34C1Q33801255-F7C1FD1E-3721-45D6-A5BD-4D39B71FD0F7Q34141457-5D2BFB02-78E2-4D04-B306-8C8C75E4EC11Q34198351-F323BC40-610A-4D13-BC0A-27131E7AE2F2Q34579038-4AADE08F-6BE2-4D7D-9F49-E4005F2190A9Q34659854-7DF97096-B868-47B1-BDFD-146196D277E8Q34687201-20BA6310-8A6C-4376-9C05-8E73A8AFFE80Q35067947-BF4B5A84-5B45-4E95-BC5B-0B59C80853CFQ35131272-8AB9AEF3-394A-4144-B85B-F0B9E9F55D41Q35160045-13F64A75-737E-4086-BF12-267044305BBBQ35347732-98BCA486-21E2-4411-A10D-9A418EC27CD2Q35462377-DF37C9F1-807A-4831-B6E9-A01C3D19402DQ35681966-F70067D1-C662-41B1-80DB-025E6241C7A6Q35709269-778BA9C3-9CF1-4A99-9D2B-B6D42A1EFD9DQ35940233-1A041783-A27E-44D8-9E96-8B5229EE3397Q35972107-E5E1B164-2B2D-4384-8813-722B210EF732Q36295039-534F9A5D-02B6-4735-87B9-1D6D1ACF9E6CQ36536487-4BA5DBDE-4474-459D-85FC-682DC7CFB692Q36719073-5950743D-AFE7-46F6-BDB8-A3BD0FD2BCACQ36869233-D2D0D021-AF8B-4AC3-B3C8-B8851A545B2EQ37121271-87395F29-6F6B-4846-B912-5D8BF532F4F1Q37350137-A79FBE94-F19F-4B94-BCB7-7A0FCCDB4D87Q37463125-E132FA11-B1B6-4F5C-B2B3-1F0EAB8D5797Q37520405-69ACF880-73F9-44D0-AE78-9FDFFA8CE54AQ38077896-17B04936-8488-496F-B5FC-277B9A45C80DQ38960732-66B4F888-E5A2-4A54-8524-0C451958625AQ40288116-82018105-4158-40DF-A545-88F670F73510Q40362934-FD33D83D-D288-444B-98B3-B11F4FB1E165Q40626929-E78BC534-B2AB-4CF4-9C24-2EB3667167AEQ44543683-DE43AD22-0B3A-49D1-B128-06F4617A5B22Q44585456-4E4ECF7B-F33A-4E0D-B606-0966D711FB24Q44966169-83F6F626-7612-4A7B-B703-1FE062A20E4CQ48212372-62F118FC-D70C-43A2-8303-DAD3B2F5B55CQ48511251-E713827B-98C9-4FC3-96D3-B7CBCAAD9E83Q51122740-DCB4A52B-E355-4705-910C-D3E0BD03A958Q51380793-2653F142-4983-440F-8477-31B206ADFEF0
P2860
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@ast
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@en
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@nl
type
label
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@ast
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@en
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@nl
prefLabel
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@ast
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@en
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@nl
P2093
P2860
P1433
P1476
Proliferative activity in huma ...... nt Ki-67 equivalent antibodies
@en
P2093
C Cantaloni
D Aldovini
E Bragantini
E Leonardi
F Gasperetti
G Berlanda
I Bazzanella
L V Cuorvo
P2860
P2888
P356
10.1186/1746-1596-6-S1-S7
P478
P577
2011-03-30T00:00:00Z
P6179
1019141053